Pelareorep is a virus that preferentially invades cancer cells that have an increased RAS level. They can kill tumor cells themselves and increase immune response due to the virus.


Results of pelareorep combined with paclitaxel and avelumab (PD-L1 inhibitor) in HR+/HER2- advanced or metastatic breast cancer.

Quote:

---

Results of the final BRACELET-1 analysis show that the median OS was not reached in the pelareorep + paclitaxel arm, as more than half of the patients in that arm remained alive at study end. In contrast, median OS for the paclitaxel monotherapy arm was 18.2 months, and the hazard ratio was 0.48 for pelareorep + paclitaxel vs. the paclitaxel monotherapy. Had study follow-up continued beyond two years, and patients survived only until the next planned visit (in four months), the median OS for patients in the pelareorep + paclitaxel arm would be 32.1 months. In accordance with these results, the two-year survival rate for patients in the pelareorep + paclitaxel arm was 64% compared to 33% for paclitaxel monotherapy patients. Additionally, the final median progression-free survival (PFS) for BRACELET-1 was 12.1 months in the pelareorep + paclitaxel arm vs. 6.4 months in the paclitaxel monotherapy arm, representing a 5.7-month benefit
https://www.prnewswire.com/news-releases/onco...3060.html#

---

Take into account that HR+/HER2- has the highest long term survival rate compared to the lowest for TNBC. HR+/HER2- is four times better. It will be interesting to see what leronlimab can do in the HR+/HER2- space,